Axsome Therapeutics price target raised to $304 from $302 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm's price target on Axsome Therapeutics to $304 from $302 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move i